MSI-话题@MedSci

#MSI#

37篇内容 | 1938人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1581115, encodeId=20df158111586, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=82, createdTime=2021-01-21, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581114, encodeId=ed171581114fc, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, objectType=article, longId=205086, objectId=4d4920508636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d4920508636, replyNumber=0, likeNumber=67, createdTime=2021-01-02, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d4920508636, moduleTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d4920508636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581113, encodeId=46a41581113cb, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=MSI-H/dMMR晚期实体瘤：各家PD-1/PD-L1表现如何？, objectType=article, longId=203620, objectId=e4af20362026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4af20362026, replyNumber=0, likeNumber=61, createdTime=2020-11-23, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4af20362026, moduleTitle=MSI-H/dMMR晚期实体瘤：各家PD-1/PD-L1表现如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4af20362026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581112, encodeId=6d0d158111257, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, objectType=article, longId=198566, objectId=a45b198566bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45b198566bc, replyNumber=0, likeNumber=62, createdTime=2020-08-03, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45b198566bc, moduleTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45b198566bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581111, encodeId=c21b1581111a9, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Eur J Hum Genet：丁培荣教授解说林奇综合征初筛结果为MSI-H/dMMR，下一步该做什么检测？, objectType=article, longId=197997, objectId=6efc19e99773, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6efc19e99773, replyNumber=0, likeNumber=63, createdTime=2020-07-26, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6efc19e99773, moduleTitle=Eur J Hum Genet：丁培荣教授解说林奇综合征初筛结果为MSI-H/dMMR，下一步该做什么检测？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6efc19e99773)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581110, encodeId=967f158111064, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号, objectType=article, longId=197298, objectId=6b4219e29846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b4219e29846, replyNumber=0, likeNumber=69, createdTime=2020-07-11, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b4219e29846, moduleTitle=泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b4219e29846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581109, encodeId=53e7158110956, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, objectType=article, longId=196815, objectId=70ef1968157f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef1968157f, replyNumber=0, likeNumber=56, createdTime=2020-07-02, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef1968157f, moduleTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ef1968157f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581108, encodeId=5d311581108ad, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, objectType=article, longId=195301, objectId=db5919530147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db5919530147, replyNumber=0, likeNumber=90, createdTime=2020-06-06, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db5919530147, moduleTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db5919530147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581107, encodeId=9dbd158110e2f, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Bone Joint J：基于MSIS标准的FDG PET在假体关节感染中的诊断作用, objectType=article, longId=195052, objectId=6c14195052a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c14195052a0, replyNumber=0, likeNumber=163, createdTime=2020-06-02, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c14195052a0, moduleTitle=Bone Joint J：基于MSIS标准的FDG PET在假体关节感染中的诊断作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c14195052a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581106, encodeId=d5a115811063e, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Clinica Chimica Acta：通过对25种癌症类型的MSIcall进行靶向测序来确定微卫星的不稳定性状态, objectType=article, longId=192157, objectId=de1e19215eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e19215eaf, replyNumber=0, likeNumber=69, createdTime=2020-04-14, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e19215eaf, moduleTitle=Clinica Chimica Acta：通过对25种癌症类型的MSIcall进行靶向测序来确定微卫星的不稳定性状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de1e19215eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581105, encodeId=ad7c15811052f, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, objectType=article, longId=183993, objectId=3c02183993a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c02183993a4, replyNumber=0, likeNumber=36, createdTime=2019-12-04, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c02183993a4, moduleTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c02183993a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581104, encodeId=68c11581104a3, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高, objectType=article, longId=179912, objectId=89001e991243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89001e991243, replyNumber=0, likeNumber=67, createdTime=2019-09-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89001e991243, moduleTitle=2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89001e991243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581103, encodeId=cea31581103a0, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=李健教授：小众迷离，MSI-H肠癌肝转移如何精准治疗？, objectType=article, longId=178599, objectId=699a1e85993e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=699a1e85993e, replyNumber=0, likeNumber=60, createdTime=2019-09-04, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=699a1e85993e, moduleTitle=李健教授：小众迷离，MSI-H肠癌肝转移如何精准治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=699a1e85993e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581102, encodeId=b552158110232, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=MSI/MMR检测在胃肠肿瘤中的临床意义及价值, objectType=article, longId=173278, objectId=104f1e32787d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=104f1e32787d, replyNumber=0, likeNumber=64, createdTime=2019-06-28, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=104f1e32787d, moduleTitle=MSI/MMR检测在胃肠肿瘤中的临床意义及价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=104f1e32787d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581101, encodeId=234f158110152, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, objectType=article, longId=168267, objectId=22fc16826e29, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22fc16826e29, replyNumber=0, likeNumber=94, createdTime=2019-06-14, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22fc16826e29, moduleTitle=实体瘤患者PD-L1表达与TMB、MSI的相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22fc16826e29)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581100, encodeId=0648158110080, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Biomed Res Int：mSIS可作为GBR的生物相容性膜, objectType=article, longId=144769, objectId=23b8144e69a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b8144e69a8, replyNumber=0, likeNumber=0, createdTime=2018-07-21, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b8144e69a8, moduleTitle=Biomed Res Int：mSIS可作为GBR的生物相容性膜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b8144e69a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581099, encodeId=3b6e1581099e6, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Future Oncol：适合于东亚结直肠癌患者MSI检测位点新研究, objectType=article, longId=142579, objectId=86831425e9f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86831425e9f7, replyNumber=0, likeNumber=76, createdTime=2018-07-07, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86831425e9f7, moduleTitle=Future Oncol：适合于东亚结直肠癌患者MSI检测位点新研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86831425e9f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581098, encodeId=273915810987e, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, objectType=article, longId=127483, objectId=749e12e48327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749e12e48327, replyNumber=0, likeNumber=64, createdTime=2018-01-25, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749e12e48327, moduleTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749e12e48327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581097, encodeId=c336158109e10, content=<a href='/topic/show?id=a8ec122803c' target=_blank style='color:#2F92EE;'>#MSI#</a>, objectTitle=Lancet Oncol：纳武单抗用于dMMR/MSI-H转移性结直肠癌显示出了令人鼓舞的疗效, objectType=article, longId=107084, objectId=001f10e0841a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=001f10e0841a, replyNumber=0, likeNumber=68, createdTime=2017-07-30, rootId=0, userName=小几洁, userId=f65a16715482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=001f10e0841a, moduleTitle=Lancet Oncol：纳武单抗用于dMMR/MSI-H转移性结直肠癌显示出了令人鼓舞的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=001f10e0841a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MSI

2020-05-29

小几洁 (审核中...)

前往app查看评论内容

#MSI#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-01-21

小几洁 (审核中...)

前往app查看评论内容

#MSI#

中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA

2021-01-02

小几洁 (审核中...)

前往app查看评论内容

#MSI#

MSI-H/dMMR晚期实体瘤：各家PD-1/PD-L1表现如何？

2020-11-23

小几洁 (审核中...)

前往app查看评论内容

#MSI#

抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟

2020-08-03

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Eur J Hum Genet：丁培荣教授解说林奇综合征初筛结果为MSI-H/dMMR，下一步该做什么检测？

2020-07-26

小几洁 (审核中...)

前往app查看评论内容

#MSI#

泛发性脓疱型银屑病：Imsidolimab获FDA孤儿药称号

2020-07-11

小几洁 (审核中...)

前往app查看评论内容

#MSI#

FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法

2020-07-02

小几洁 (审核中...)

前往app查看评论内容

#MSI#

ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位

2020-06-06

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Bone Joint J：基于MSIS标准的FDG PET在假体关节感染中的诊断作用

2020-06-02

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Clinica Chimica Acta：通过对25种癌症类型的MSIcall进行靶向测序来确定微卫星的不稳定性状态

2020-04-14

小几洁 (审核中...)

前往app查看评论内容

#MSI#

欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎

2019-12-04

智慧医人 (审核中...)

前往app查看评论内容

#MSI#

2019 CSCO：抗PD-L1抗体CS1001治疗MSI-H实体瘤有效性好、安全性高

2019-09-24

小几洁 (审核中...)

前往app查看评论内容

#MSI#

李健教授：小众迷离，MSI-H肠癌肝转移如何精准治疗？

2019-09-04

小几洁 (审核中...)

前往app查看评论内容

#MSI#

MSI/MMR检测在胃肠肿瘤中的临床意义及价值

2019-06-28

小几洁 (审核中...)

前往app查看评论内容

#MSI#

实体瘤患者PD-L1表达与TMB、MSI的相关性研究

2019-06-14

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Biomed Res Int：mSIS可作为GBR的生物相容性膜

2018-07-21

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Future Oncol：适合于东亚结直肠癌患者MSI检测位点新研究

2018-07-07

小几洁 (审核中...)

前往app查看评论内容

#MSI#

J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代

2018-01-25

小几洁 (审核中...)

前往app查看评论内容

#MSI#

Lancet Oncol：纳武单抗用于dMMR/MSI-H转移性结直肠癌显示出了令人鼓舞的疗效

2017-07-30

科室
- - 订阅+
  - 更多科室
工具
服务